LabCorp's revenues jump after Covance buyout; Regen taps Charles River for preclinical project;

> In its first quarter after acquiring CRO giant Covance, LabCorp's ($LH) revenue jumped 23.9% to $1.4 billion. Covance's revenue decreased 1.9% to $624.6 million compared with the same period last year. Results

> Regen BioPharma has tapped Charles River Laboratories ($CRL) to run a preclinical study on its cell therapy designed to repair bone marrow. News

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.